BRPI0918253A2 - aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele - Google Patents

aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele

Info

Publication number
BRPI0918253A2
BRPI0918253A2 BRPI0918253A BRPI0918253A BRPI0918253A2 BR PI0918253 A2 BRPI0918253 A2 BR PI0918253A2 BR PI0918253 A BRPI0918253 A BR PI0918253A BR PI0918253 A BRPI0918253 A BR PI0918253A BR PI0918253 A2 BRPI0918253 A2 BR PI0918253A2
Authority
BR
Brazil
Prior art keywords
skin
therapeutic agents
mucous membranes
improved absorption
absorption
Prior art date
Application number
BRPI0918253A
Other languages
English (en)
Inventor
Andrew Lester Lewis
Faron Michael Jordan
Lisbeth Illum
Original Assignee
Critical Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0816642A external-priority patent/GB0816642D0/en
Priority claimed from GB0820799A external-priority patent/GB0820799D0/en
Application filed by Critical Pharmaceuticals Ltd filed Critical Critical Pharmaceuticals Ltd
Publication of BRPI0918253A2 publication Critical patent/BRPI0918253A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0918253A 2008-09-12 2009-09-14 aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele BRPI0918253A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0816642A GB0816642D0 (en) 2008-09-12 2008-09-12 Compositions for Improved Absorption of a Therapeutic Agent across a Mucosal Membrane
GB0820799A GB0820799D0 (en) 2008-11-13 2008-11-13 Compositions for improved absorption of a therapeutic agent across muscosal membrane or the skin
PCT/GB2009/051188 WO2010029374A1 (en) 2008-09-12 2009-09-14 Improvements in the absorption of therapeutic agents across mucosal membranes or the skin

Publications (1)

Publication Number Publication Date
BRPI0918253A2 true BRPI0918253A2 (pt) 2015-12-15

Family

ID=41277622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918253A BRPI0918253A2 (pt) 2008-09-12 2009-09-14 aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele

Country Status (15)

Country Link
US (2) US8795634B2 (pt)
EP (1) EP2334285A1 (pt)
JP (2) JP6002385B2 (pt)
KR (1) KR20110056516A (pt)
CN (1) CN102149368B (pt)
AU (1) AU2009290656B2 (pt)
BR (1) BRPI0918253A2 (pt)
CA (1) CA2734381A1 (pt)
GB (1) GB2463565A (pt)
IL (1) IL211328A0 (pt)
MX (1) MX2011002688A (pt)
NZ (1) NZ591261A (pt)
RU (1) RU2519193C2 (pt)
WO (1) WO2010029374A1 (pt)
ZA (1) ZA201101638B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
FR2959936B1 (fr) * 2010-05-14 2012-08-03 Physica Pharma Composition nasales a visee systemique a base de cocoyl proline ou d 'au moins un de ses constituants
KR102113512B1 (ko) * 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
CN102939104A (zh) * 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
KR101134622B1 (ko) * 2010-08-12 2012-04-09 한국원자력연구원 암포테리신 ｂ의 서방성 수화겔 및 이의 제조방법
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102580056B (zh) * 2011-12-16 2014-04-09 深圳市健元医药科技有限公司 一种含抗利尿成分的缓释注射剂及其制备方法
WO2013103668A1 (en) * 2012-01-05 2013-07-11 Ala Wai Pharma Inc. Formulations for enhanced bioavailability of zanamivir
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
US8807131B1 (en) 2013-06-18 2014-08-19 Isonea Limited Compliance monitoring for asthma inhalers
MA39111A1 (fr) * 2013-11-14 2017-04-28 Eyed Pharma Dispositif oculaire
JP2016540748A (ja) * 2013-11-14 2016-12-28 インシス・ファーマ・インコーポレーテッド オンダンセトロン舌下スプレー製剤
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
CN107249678B (zh) * 2014-12-19 2021-02-19 凯敏工业公司 使用离子电渗法进行生物活性分子的眼内递送
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
CN105617353A (zh) * 2016-01-04 2016-06-01 李志海 一种黏菌素口服给药组合物
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10821156B2 (en) 2016-04-12 2020-11-03 Cell and Molecular Tissue Engineering, LLC Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site
ES3066533T3 (en) 2016-11-02 2026-05-13 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
JP7143335B2 (ja) 2017-03-02 2022-09-28 ダッチ・リニューアブル・エナジー・ビー．ブイ． 生理活性物質の鼻腔内投与
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3684338A4 (en) 2017-09-22 2021-06-23 Otitopic Inc. DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN108535398B (zh) * 2018-04-04 2020-03-27 福州海王福药制药有限公司 一种采用反相高效液相色谱法分离盐酸噻加宾手性对映体的方法
CN110384656A (zh) * 2018-04-19 2019-10-29 上海现代药物制剂工程研究中心有限公司 依达拉奉鼻腔给药组合物及其鼻给药制剂制备方法
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
SMT202100034T1 (it) 2018-07-12 2021-03-15 Nicox Sa Composizioni oftalmiche contenenti una prostamide che rilascia ossido nitrico
KR102086316B1 (ko) * 2019-09-09 2020-03-09 한국콜마주식회사 경피흡수성이 우수한 화장료 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
CN110755380B (zh) * 2019-11-04 2021-09-24 中国人民解放军军事科学院军事医学研究院 一种甲状旁腺激素1-34鼻喷剂、其制备方法及用途
EP4601697A2 (en) * 2022-10-13 2025-08-20 NBI Biosciences Pvt Ltd A formulation for oral delivery of peptides and biosimilars for systemic absorption and method of manufacturing the same
CN118121542A (zh) * 2023-03-31 2024-06-04 中国药科大学 鼻用药物组合物、其制备方法及应用
CN118121543A (zh) * 2023-03-31 2024-06-04 中国药科大学 鼻用药物组合物、其制备方法及应用
KR102705817B1 (ko) * 2024-02-05 2024-09-12 주식회사 대웅제약 비강 스프레이용 조성물 및 그 제조방법
WO2025229073A1 (en) * 2024-05-01 2025-11-06 Fastox Pharma Sa Aqueous compositions of dantrolene
CN120114390B (zh) * 2025-04-09 2026-03-31 南通香地生物有限公司 一种他克莫司透皮气雾剂及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5320850A (en) * 1990-10-29 1994-06-14 Alza Corporation Transdermal delivery of the gestogen ST-1435 and devices therefor
DE19544507B4 (de) * 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
AU4717997A (en) 1996-10-28 1998-05-22 Farmarc Nederland Bv Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
SE9704833D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New formulation
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
AU768785B2 (en) * 1999-04-13 2004-01-08 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Solubilized pharmaceutical composition for parenteral administration
FR2798288B1 (fr) 1999-09-14 2001-11-30 Capsulis Compositions vaccinales destinees a une administration par voie muqueuse
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050063940A1 (en) 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
WO2003099264A1 (en) 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
JP2006515629A (ja) 2003-01-23 2006-06-01 シャイア ラボラトリーズ，インコーポレイテッド 吸収促進剤
US20060073196A1 (en) 2003-02-12 2006-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of p-glycoprotein inhibitor surfactants at the surface of a colloidal carrier
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
EP1643970A2 (en) * 2003-06-09 2006-04-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
WO2004113332A1 (ja) * 2003-06-19 2004-12-29 Ono Pharmaceutical Co., Ltd. 経鼻製剤
WO2005094785A2 (en) * 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
US20050136103A1 (en) * 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
WO2006097793A2 (en) * 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
AU2005237580B2 (en) 2004-04-28 2011-06-16 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
US20060078616A1 (en) * 2004-08-30 2006-04-13 Georgewill Dawaye A Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
DE102004046235A1 (de) * 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
CZ297215B6 (cs) * 2005-04-06 2006-10-11 Zentiva, A. S. Topická léková forma s obsahem nimesulidu
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
FR2887150B1 (fr) * 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
ITRM20050418A1 (it) 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
DE102005037662A1 (de) * 2005-08-05 2007-02-08 Tesa Ag Klebeband mit einem Träger aus einem Spinnvlies, der einseitig mit einem druckempfindlichen Kleber zumindest partiell beschichtet ist
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20090123543A1 (en) * 2006-01-02 2009-05-14 Rubicon Research Private Limited Pharmaceutical compositions
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
AU2007312233B2 (en) 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
WO2008058234A2 (en) 2006-11-08 2008-05-15 Memory Pharmaceuticals Corporation Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
WO2008101344A1 (en) 2007-02-22 2008-08-28 Peter Tomlinson Soluble bioactive lipophilic compounds compositions
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination

Also Published As

Publication number Publication date
AU2009290656B2 (en) 2015-05-07
RU2519193C2 (ru) 2014-06-10
GB0916028D0 (en) 2009-10-28
US8795634B2 (en) 2014-08-05
JP2015042689A (ja) 2015-03-05
RU2011114078A (ru) 2012-10-20
MX2011002688A (es) 2011-04-12
AU2009290656A1 (en) 2010-03-18
GB2463565A (en) 2010-03-24
IL211328A0 (en) 2011-04-28
NZ591261A (en) 2012-12-21
CN102149368A (zh) 2011-08-10
JP2012502087A (ja) 2012-01-26
JP6002385B2 (ja) 2016-10-05
KR20110056516A (ko) 2011-05-30
WO2010029374A1 (en) 2010-03-18
EP2334285A1 (en) 2011-06-22
CA2734381A1 (en) 2010-03-18
US20110171140A1 (en) 2011-07-14
US20140072588A1 (en) 2014-03-13
CN102149368B (zh) 2017-02-08
ZA201101638B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
FIC20240036I1 (fi) Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
BRPI0906389A2 (pt) Sistema de terapia de pele
IL211328A0 (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
BRPI1013409A2 (pt) células de tecido de cordão umbilical humano como terapia para doença de alzheimer
BRPI0917567A2 (pt) tratamento de doença respiratória
BR112012028592A2 (pt) método para fabricação de uma composição de glicosaminoglicano, composição de glicosaminoglicano, seus usos e preparação adequada para aplicação à pele ou membrana mucosa
BRPI0716592A2 (pt) Composição para cuidado da pele
EP2498708A4 (en) DEVICE FOR HOLLOW-BODY HOLLOW ABLATION
BRPI0922823A2 (pt) Combinações e modos de administração de agentes terapêuticos e terapia de combinação
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI1012129A2 (pt) enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI0907918A2 (pt) Ácidos sulfoperoxicarxílicos, sua preparação e métodos de utilizção como agentes alvejantes e antimicrobianos
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
EP2125002A4 (en) TREATMENT OF SKIN CANCER
BRPI0820477A2 (pt) Compostos de benzodiazepinona úteis no tratamento de afecções da pele
BRPI1006024B8 (pt) composição cosmética emulsificada para cuidado da pele
BRPI1013486A2 (pt) composições aquosas de limpeza de cabelos e pele
BRPI0716671A2 (pt) Produto semi-acabado na fabricação de uma composição para cuidado da pele ou do cabelo
PT2613798E (pt) Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes
BR112013016337A2 (pt) sistema de tratamento médico com fibra óptica
EP2387418A4 (en) PAIN TREATMENT
BR112012004515A2 (pt) "monitoramento por ultrassom de tratamentos estéticos"
EP2247297A4 (en) THERAPEUTIC TREATMENT OF LUNG DISEASES
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.